메뉴 건너뛰기




Volumn 14, Issue 2, 2004, Pages 224-228

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

Author keywords

Altretamine; Consolidation therapy; Hexamethylmelamine; Ovarian cancer

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; TOPOTECAN;

EID: 2042487233     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.014204.x     Document Type: Article
Times cited : (26)

References (20)
  • 2
    • 0036200879 scopus 로고    scopus 로고
    • Survival among U.S. women with invasive epithelial ovarian cancer
    • McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002;84:399-403.
    • (2002) Gynecol Oncol , vol.84 , pp. 399-403
    • McGuire, V.1    Jesser, C.A.2    Whittemore, A.S.3
  • 3
    • 0036498788 scopus 로고    scopus 로고
    • Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
    • Bristow RE, Tomacruz RS, Armstrong DK, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
    • (2002) J Clin Oncol , vol.20 , pp. 1248-1259
    • Bristow, R.E.1    Tomacruz, R.S.2    Armstrong, D.K.3    Montz, F.J.4
  • 4
    • 0030054309 scopus 로고    scopus 로고
    • Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
    • McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
    • (1996) N Engl J Med , vol.334 , pp. 1-6
    • McGuire, W.P.1    Hoskins, W.J.2    Brady, M.F.3
  • 5
    • 0000121237 scopus 로고    scopus 로고
    • Randomized phase III study of cisplatin (CIS) /paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
    • Ozols RF, Bundy BN, Fowler J et al. Randomized phase III study of cisplatin (CIS) /paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158) [Abstract 1373]. Proc ASCO 1999;18:356a.
    • (1999) Proc ASCO , vol.18
    • Ozols, R.F.1    Bundy, B.N.2    Fowler, J.3
  • 6
    • 0002324260 scopus 로고    scopus 로고
    • Survival and longer-term toxicity results of the SCOTROC study: Docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC)
    • Vasey PA. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) [Abstract 804]. Proc ASCO 2002;21:202a.
    • (2002) Proc ASCO , vol.21
    • Vasey, P.A.1
  • 7
    • 0030698757 scopus 로고    scopus 로고
    • Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
    • Efsenhauer EA, Vermorken JM, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-8.
    • (1997) Ann Oncol , vol.8 , pp. 963-968
    • Efsenhauer, E.A.1    Vermorken, J.M.2    Van Glabbeke, M.3
  • 8
    • 0034049605 scopus 로고    scopus 로고
    • Second-line treatment of ovarian cancer
    • Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35.
    • (2000) Oncologist , vol.5 , pp. 26-35
    • Markman, M.1    Bookman, M.A.2
  • 10
    • 0031028270 scopus 로고    scopus 로고
    • Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125
    • Rustin GJ, Nelstrop AE, Crawford M et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172-6.
    • (1997) J Clin Oncol , vol.15 , pp. 172-176
    • Rustin, G.J.1    Nelstrop, A.E.2    Crawford, M.3
  • 11
    • 0031193915 scopus 로고    scopus 로고
    • Hexamethylmelamine as a single second-line agent in ovarian cancer: Follow-up report and review of the literature
    • Manetta A, Tewari K, Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol 1997;66:20-6.
    • (1997) Gynecol Oncol , vol.66 , pp. 20-26
    • Manetta, A.1    Tewari, K.2    Podczaski, E.S.3
  • 12
    • 0032103330 scopus 로고    scopus 로고
    • Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: A Gynecologic Oncology Group phase II trial
    • Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998;69:226-9.
    • (1998) Gynecol Oncol , vol.69 , pp. 226-229
    • Markman, M.1    Blessing, J.A.2    Moore, D.3    Ball, H.4    Lentz, S.S.5
  • 13
    • 0035072411 scopus 로고    scopus 로고
    • Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer
    • Malik IA. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn J Clin Oncol 2001;31:69-73.
    • (2001) Jpn J Clin Oncol , vol.31 , pp. 69-73
    • Malik, I.A.1
  • 14
    • 0034897130 scopus 로고    scopus 로고
    • Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III ovarian cancer: A Southwest Oncology Group trial (SWOG-9326)
    • Rothenberg ML, Liu PY, Wilcznski S et al. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol 2001;82:317-22.
    • (2001) Gynecol Oncol , vol.82 , pp. 317-322
    • Rothenberg, M.L.1    Liu, P.Y.2    Wilcznski, S.3
  • 15
    • 0026634982 scopus 로고
    • Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a Phase III randomized trial in stages III and IV ovarian cancer
    • Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a Phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-11.
    • (1992) J Clin Oncol , vol.10 , pp. 706-711
    • Alberts, D.S.1    Green, S.2    Hannigan, E.V.3
  • 16
    • 0346423733 scopus 로고    scopus 로고
    • Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
    • Alberts DS, Lui PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med 1996;335:1950-5.
    • (1996) New Engl J Med , vol.335 , pp. 1950-1955
    • Alberts, D.S.1    Lui, P.Y.2    Hannigan, E.V.3
  • 17
    • 0035865144 scopus 로고    scopus 로고
    • Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
    • Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
    • (2001) J Clin Oncol , vol.19 , pp. 1001-1007
    • Markman, M.1    Bundy, B.N.2    Alberts, D.S.3
  • 18
    • 0034886499 scopus 로고    scopus 로고
    • Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-1 inhibitors and perspective of the Gynecologic Oncology Group
    • Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-1 inhibitors and perspective of the Gynecologic Oncology Group. Int J Gynecol Cancer, 2001;11 (Suppl. 1):42-51.
    • (2001) Int J Gynecol Cancer , vol.11 , Issue.SUPPL. 1 , pp. 42-51
    • Bookman, M.A.1
  • 19
    • 0038690538 scopus 로고    scopus 로고
    • Phase III randomized trial of 12 versus 3 months if maintenance paclitaxel in patients with advanced ovarian cancer after complete recovery to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
    • Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months if maintenance paclitaxel in patients with advanced ovarian cancer after complete recovery to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-73.
    • (2003) J Clin Oncol , vol.21 , pp. 2460-2473
    • Markman, M.1    Liu, P.Y.2    Wilczynski, S.3
  • 20
    • 0034600305 scopus 로고    scopus 로고
    • Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
    • Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst, 2000;92:699-708.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 699-708
    • Piccart, M.J.1    Bertelsen, K.2    James, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.